CD 93 Marks a Non-Quiesc ent Human Leukemia Stem Cell Population and Is Required for Development of MLL-Rearranged Acute Myeloid Leukemia Graphical

[1]  Stefan Fröhling,et al.  Requirement for CDK6 in MLL-rearranged acute myeloid leukemia. , 2013, Blood.

[2]  Angelo J. Canty,et al.  Stem cell gene expression programs influence clinical outcome in human leukemia , 2011, Nature Medicine.

[3]  Ash A. Alizadeh,et al.  Prospective separation of normal and leukemic stem cells based on differential expression of TIM3, a human acute myeloid leukemia stem cell marker , 2011, Proceedings of the National Academy of Sciences.

[4]  M. Konopleva,et al.  Leukemia stem cells and microenvironment: biology and therapeutic targeting. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  Ash A. Alizadeh,et al.  Association of a leukemic stem cell gene expression signature with clinical outcomes in acute myeloid leukemia. , 2010, JAMA.

[6]  M. Sramko,et al.  Myeloid-specific inactivation of p15Ink4b results in monocytosis and predisposition to myeloid leukemia. , 2010, Blood.

[7]  O. Ohara,et al.  Identification of Therapeutic Targets for Quiescent, Chemotherapy-Resistant Human Leukemia Stem Cells , 2010, Science Translational Medicine.

[8]  Ash A. Alizadeh,et al.  CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem Cells , 2009, Cell.

[9]  I. Weissman,et al.  CD47 Is Upregulated on Circulating Hematopoietic Stem Cells and Leukemia Cells to Avoid Phagocytosis , 2009, Cell.

[10]  Howard Y. Chang,et al.  Hierarchical maintenance of MLL myeloid leukemia stem cells employs a transcriptional program shared with embryonic rather than adult stem cells. , 2009, Cell stem cell.

[11]  Satoshi Tanaka,et al.  Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region , 2007, Nature Biotechnology.

[12]  M. Cleary,et al.  Meis1 is an essential and rate-limiting regulator of MLL leukemia stem cell potential. , 2007, Genes & development.

[13]  I. Weissman,et al.  CD96 is a leukemic stem cell-specific marker in human acute myeloid leukemia , 2007, Proceedings of the National Academy of Sciences.

[14]  M. Cleary,et al.  Identification and characterization of leukemia stem cells in murine MLL-AF9 acute myeloid leukemia. , 2006, Cancer cell.

[15]  J. Dick,et al.  Targeting of CD44 eradicates human acute myeloid leukemic stem cells , 2006, Nature Medicine.

[16]  M. Noble,et al.  Cancer stem cells. , 2006, The New England journal of medicine.

[17]  P. Guldberg,et al.  Promoter hypermethylation of p15INK4B, HIC1, CDH1, and ER is frequent in myelodysplastic syndrome and predicts poor prognosis in early‐stage patients , 2006, European journal of haematology.

[18]  Irving L. Weissman,et al.  Global analysis of proliferation and cell cycle gene expression in the regulation of hematopoietic stem and progenitor cell fates , 2005, The Journal of experimental medicine.

[19]  G. V. van Dongen,et al.  The novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells. , 2005, Blood.

[20]  G. Sauvageau,et al.  Identification of cooperative genes for NUP98-HOXA9 in myeloid leukemogenesis using a mouse model. , 2005, Blood.

[21]  P. Sharp,et al.  Cre-lox-regulated conditional RNA interference from transgenes. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[22]  P. Taylor,et al.  Murine CD93 (C1qRp) Contributes to the Removal of Apoptotic Cells In Vivo but Is Not Required for C1q-Mediated Enhancement of Phagocytosis1 , 2004, The Journal of Immunology.

[23]  M. Malumbres,et al.  Hypermethylation of the Ink4b locus in murine myeloid leukemia and increased susceptibility to leukemia in p15Ink4b-deficient mice , 2003, Oncogene.

[24]  M. Cleary,et al.  Transformation of myeloid progenitors by MLL oncoproteins is dependent on Hoxa7 and Hoxa9. , 2003, Genes & development.

[25]  L. Larocca,et al.  Hypermethylation of GpG islands in the promoter region of p15INK4b in acute promyelocytic leukemia represses p15INK4b expression and correlates with poor prognosis , 2003, Leukemia.

[26]  Douglas R Lowy,et al.  p16INK4a gene promoter variation and differential binding of a repressor, the ras-responsive zinc-finger transcription factor, RREB , 2003, Oncogene.

[27]  M. Simon,et al.  C1qRp defines a new human stem cell population with hematopoietic and hepatic potential , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[28]  P. Gasque,et al.  Human C1qRp Is Identical with CD93 and the mNI-11 Antigen But Does Not Bind C1q1 , 2002, The Journal of Immunology.

[29]  A. Ganser,et al.  Tumor suppressor genes in normal and malignant hematopoiesis , 2002, Oncogene.

[30]  J. Nolta,et al.  Molecular mechanism of transforming growth factor b – mediated cell-cycle modulation in primary human CD 34 1 progenitors , 2001 .

[31]  E. Nelson,et al.  C1qRp, a myeloid cell receptor in blood, is predominantly expressed on endothelial cells in human tissue , 2001, Journal of leukocyte biology.

[32]  R. Liang,et al.  Methylation of p15 and p16 genes in acute promyelocytic leukemia: potential diagnostic and prognostic significance. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  C. Li,et al.  Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[34]  D. Howard,et al.  The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells , 2000, Leukemia.

[35]  L. Larocca,et al.  Expression of cyclin-dependent kinase inhibitor p15(INK4B) during normal and leukemic myeloid differentiation. , 2000, Experimental hematology.

[36]  I. Lemischka,et al.  The molecular characterization of the fetal stem cell marker AA4. , 1999, Immunity.

[37]  H. Drexler.  Review of alterations of the cyclin-dependent kinase inhibitor INK4 family genes p15, p16, p18 and p19 in human leukemia–lymphoma cells , 1998, Leukemia.

[38]  A. Tenner,et al.  C1qRP, the C1q receptor that enhances phagocytosis, is detected specifically in human cells of myeloid lineage, endothelial cells, and platelets. , 1998, Journal of immunology.

[39]  M. Cleary,et al.  Immortalization and leukemic transformation of a myelomonocytic precursor by retrovirally transduced HRX–ENL , 1997, The EMBO journal.

[40]  J. Dick,et al.  Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell , 1997, Nature Medicine.

[41]  J. Dick,et al.  Purification of primitive human hematopoietic cells capable of repopulating immune-deficient mice. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[42]  A. Henschen-Edman,et al.  cDNA cloning and primary structure analysis of C1qR(P), the human C1q/MBL/SPA receptor that mediates enhanced phagocytosis in vitro. , 1997, Immunity.

[43]  J. Herman,et al.  Hypermethylation-associated inactivation indicates a tumor suppressor role for p15INK4B. , 1996, Cancer research.

[44]  M. Caligiuri,et al.  A cell initiating human acute myeloid leukaemia after transplantation into SCID mice , 1994, Nature.

[45]  菊繁 吉謙.  TIM-3 is a promising target to selectively kill acute myeloid leukemia stem cells , 2012 .

[46]  K. Ohyashiki,et al.  Methylation of p15(INK4b) and E-cadherin genes is independently correlated with poor prognosis in acute myeloid leukemia. , 2005, Leukemia research.

[47]  I. Wong,et al.  Aberrant p15 promoter methylation in adult and childhood acute leukemias of nearly all morphologic subtypes: potential prognostic implications. , 2000, Blood.